Medicare

New & Noteworthy
Examining the Potential Impact of Medicare’s New WISeR Model

A federal initiative to establish new prior authorization requirements in traditional Medicare, called the Wasteful and Inappropriate Service Reduction (WISeR) model, is likely to have only modest impact in its first year.

State Profiles for Dual-Eligible Individuals

This data collection draws on Medicare and Medicaid administrative data to present national and state-level information on people who are covered by both Medicare and Medicaid, referred to as dual-eligible individuals (also known as dually-enrolled beneficiaries).

Data Visualization

The Facts About Medicare Spending

This interactive provides the facts on Medicare spending. Medicare, which serves 67 million people and accounts for 12 percent of the federal budget and 21 percent of national health spending, is often the focus of discussions about health expenditures, health care affordability and the sustainability of federal health programs.

Explore data on enrollment growth, Medicare spending trends overall and per person, growth in Medicare spending relative to private insurance, spending on benefits and Medicare Advantage, Part A trust fund solvency challenges, and growth in out-of-pocket spending by beneficiaries.

Related: FAQs on Medicare Financing and Trust Fund Solvency

Read More

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

571 - 580 of 1,590 Results

  • Making Medicare Work Better

    Report

    This report by the Institute for Medicare Practice at Mount Sinai School of Medicine takes a hard look at the operational challenges facing Medicare and considers incremental, structural changes to improve the management of the Medicare program from the standpoint of beneficiaries and providers.

  • Health News Index – March/April 2000

    Poll Finding

    Health News Index March/April, 2000 The March/April 2000 edition of the Kaiser Family Foundation/Harvard School of Public Health, Health News Index includes questions about major health stories covered in the news, including questions about the Supreme Court's ruling on the the Food and Drug Administration's authority to regulate the marketing of tobacco products.

  • National Survey on Medicare: The Next Big Health Policy Debate? – News Release

    Other Post

    National Survey Suggests Need for Broad Public Debate About Medicare Reform:Americans Know Medicare Faces Problems, But Not Ready To Make Hard Choices Future Options Not Well UnderstoodFew Know About Medicare+Choice Embargoed For Release Until: Noon, Tuesday, October 20, 1998 For further information contact: Matt James or Tina Hoff (650) 854-9400 or Sara Knoll (202) 347-5270…

  • Post-Election Survey: Priorities for the 106th Congress

    Poll Finding

    A national voter survey by the Kaiser Family Foundation and Harvard School of Public Health conducted shortly after the November congressional elections in 1998. The purpose is to gauge voters' priorities for the next Congress, both generally and with specific regard to health care issues.

  • The Faces of Medicare

    Fact Sheet

    The Medicare beneficiary population is often described in homogenous terms, yet those covered by the program vary significantly in terms of their health, income, supplemental insurance status, and medical service use.

  • Medicare Advantage in 2025: Enrollment Update and Key Trends

    Issue Brief

    In 2025, more than half (54%) of eligible Medicare beneficiaries are enrolled in Medicare Advantage plans. This brief provides current information about Medicare Advantage enrollment, by plan type and firm, and shows how enrollment varies by state and county.

  • Recent Trends in GLP-1 Use and Spending in Medicare

    Issue Brief

    Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare’s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS’s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.